Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 8/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170938 | 0.86 | PDE4B (0.52) | PDE4BPDE3AMAPKAPK2PARP10PARP11 | |
| SCHEMBL2173651 | 0.76 | PDE4B (0.53) | PDE4BPDE3APDE4D | |
| SCHEMBL2173222 | 0.75 | PDE4B (0.54) | PDE4BPDE3AMAPKAPK2GSK3B | |
| SCHEMBL2231876 | 0.74 | PDE4B (0.48) | PDE4BPDE3A | |
| SCHEMBL2170763 | 0.73 | PARP10 (0.47) | MAPKAPK2PARP10PARP11MAPK1GSK3B | |
| SCHEMBL2171767 | 0.70 | PARP10 (0.48) | PDE4BPDE3AMAPKAPK2PARP10PARP11 | |
| SCHEMBL2215699 | 0.70 | PDE4B (0.58) | PDE4BPDE3A | |
| SCHEMBL8161680 | 0.69 | PARP11 (0.68) | MAPKAPK2PARP10PARP11GSK3BGRM5 | |
| SCHEMBL7945713 | 0.69 | PDE4B (0.53) | PDE4BPDE3A | |
| SCHEMBL12230826 | 0.68 | PARP10 (0.56) | MAPKAPK2PARP10PARP11GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | claimed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | claimed |
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | PDE4B 6/4885PDE3A 1/4885MAPKAPK2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.